carbon nanoparticles
Phase 3Small molecule
carbon nanoparticles is one of 54 small molecule programs targeting Gastric Cancer. It is currently in Phase 3.
2
Indications
3
Total Trials
0
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
714 competitors in Gastric Cancer
#DrugCompanyPhaseTrials
1Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
CAR T Cells
CChongqing Precision Biotech Co., Ltd
Phase 3
carbon nanoparticles
PPeking University Cancer Hospital & Institute
Phase 3
Gemzar
Johnson & JohnsonPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
S1,
CChinese Academy of Medical Sciences
Preclinical
PD-1 Inhibitor
Johnson & JohnsonPreclinical
Induction Phase1
GenmabPreclinical
Glutamine
SanofiPreclinical
Human Albumin
TTonghua Anrate Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Thyroid Cancer1 trial
Gastric Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for carbon nanoparticles. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details